title: A pilot study to determine the safety and feasibility of oropharyngeal administration of own mother's colostrum to extremely low-birth-weight infants.
abstract: Own mother's colostrum is rich in cytokines and other immune agents that may stimulate oropharyngeal-associated lymphoid tissue if administered oropharyngeally to extremely low-birth-weight (ELBW) infants during the first days of life when enteral feeding is contraindicated. However, the safety and feasibility of the oropharyngeal route for the administration of colostrum have not been determined.
  
  
  OBJECTIVE
  To determine the safety of oropharyngeal administration of own mother's colostrum to ELBW infants in first days of life. A secondary purpose was to investigate the feasibility of (1) delivering this intervention to ELBW infants in the first days of life and (2) measuring concentrations of secretory immunoglobulin A and lactoferrin in tracheal aspirate secretions and urine of these infants.
  
  
  METHODS
  Five ELBW infants (mean birth weight and gestational age = 657 g and 25.5 weeks, respectively).
  
  
  METHODS
  Quasi-experimental, 1 group, pretest-posttest design.
  
  
  METHODS
  Subjects received 0.2 mL of own mother's colostrum administered oropharyngeally every 2 hours for 48 consecutive hours, beginning at 48 hours of life. Concentrations of secretory immunoglobulin A and lactoferrin were measured in tracheal aspirates and urine of each subject at baseline, at the completion of the intervention and again 2 weeks later.
  
  
  RESULTS
  All infants completed the entire treatment protocol, each receiving 24 treatments. A total of 15 urine specimens were collected and 14 were sufficient in volume for analysis. A total of 15 tracheal aspirates were collected, but only 7 specimens (47%) were sufficient in volume for analysis. There was wide variation in concentrations of secretory immunoglobulin A and lactoferrin in urine and tracheal aspirates among the 5 infants; however, several results were outside the limits of assay detection. All infants began to suck on the endotracheal tube during the administration of colostrum drops. Oxygen saturation measures remained stable or increased slightly during each of the treatment sessions. There were no episodes of apnea, bradycardia, hypotension, or other adverse effects associated with the administration of colostrum.
  
  
  CONCLUSIONS
  Oropharyngeal administration of own mother's colostrum is easy, inexpensive, and well-tolerated by even the smallest and sickest ELBW infants. Future research should continue to examine the optimal procedure for measuring the direct immune effects of this therapy, as well as the clinical outcomes such as infections, particularly ventilator-associated pneumonia.
authors.affiliation: NorthShore University HealthSystem, Chicago, Illinois, USA. nrodriguez@northshore.org
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Rodriguez
authors.forename: Paula P
authors.initials: PP
authors.lastname: Meier
authors.forename: Maureen W
authors.initials: MW
authors.lastname: Groer
authors.forename: Janice M
authors.initials: JM
authors.lastname: Zeller
authors.forename: Janet L
authors.initials: JL
authors.lastname: Engstrom
authors.forename: Lou
authors.initials: L
authors.lastname: Fogg
mesh_terms: D000284:Administration, Oral; D012634:Bodily Secretions / Q000378:metabolism; D003126:Colostrum / Q000276:immunology*; D004750:Enteral Nutrition / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000378:metabolism* / Q000652:urine; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D007781:Lactoferrin / Q000378:metabolism* / Q000652:urine; D008297:Male; D010865:Pilot Projects; D014132:Trachea / Q000276:immunology
chemical_list: D007071:Immunoglobulin A, Secretory; D007781:Lactoferrin